Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
3
Bullish
8
Bearish
35
Neutral
3
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Bearish
3
Neutral
3
Bullish
8
Bearish
3
Neutral
3
Bullish
8
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Discovery themes featuring this stockWanbury Ltd (WANBURY) is currently trading at 178.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Core business: Wanbury Limited is an India-listed pharmaceutical company focused on manufacturing and exporting Active Pharmaceutical Ingredients (APIs) alongside a domestic branded formulations business, operating USFDA and EUGMP-approved manufacturing sites at Tanuku and Patalganga and exporting APIs to over fifty countries while maintaining pan-India formulations distribution. Q1 FY27 highlights: Revenue was Rs.165.6 crore, a modest 1.5% year-on-year increase, but gross margin contracted to 52.5% and EBITDA fell to Rs.16.6 crore due to an unprecedented spike in solvent and crude-linked inputs and logistics delays arising from the West Asia crisis, leading to a material decline in PAT for the quarter. Financial remediation: The company completed refinancing of Rs.205 crore of borrowings with Axis Finance and Poonawalla Fincorp, lowering borrowing costs from 12.5% to sub-10% per annum effective 1 July 2026, and releasing promoter share pledge on 40.65% of equity, which should reduce finance costs and support margin recovery from Q2FY27 onwards. Regulatory and commercial momentum: Wanbury cleared high‑profile inspections—Tanuku inspected by Australia’s TGA (enabling three additional API shipments once GMP certified) and Patalganga cleared Korea MFDS with zero observations—while expanding DMF filings into multiple geographies and receiving a No DME deficiency letter from the USFDA for Metformin API references.
Over the past 52 weeks, Wanbury Ltd has traded between a low of ₹161.50 and a high of ₹358.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Wanbury Ltd has a market capitalization of approximately 624.16. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Wanbury Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 14.52 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 624.16 Cr, Wanbury Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Wanbury Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Wanbury Ltd is 14.52. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The preview table lists Q1 FY27E revenue in the range of ₹143-165 crore, based on a Q1 FY26 base revenue of about ₹164 crore.
Core business: Wanbury Limited is an India-listed pharmaceutical company focused on manufacturing and exporting Active Pharmaceutical Ingredients (APIs) alongside a domestic branded formulations business, operating USFDA and EUGMP-approved manufacturing sites at Tanuku and Patalganga and exporting APIs to over fifty countries while maintaining pan-India formulations distribution.
Q1 FY27 highlights: Revenue was Rs.165.6 crore, a modest 1.5% year-on-year increase, but gross margin contracted to 52.5% and EBITDA fell to Rs.16.6 crore due to an unprecedented spike in solvent and crude-linked inputs and logistics delays arising from the West Asia crisis, leading to a material decline in PAT for the quarter.
Financial remediation: The company completed refinancing of Rs.205 crore of borrowings with Axis Finance and Poonawalla Fincorp, lowering borrowing costs from 12.5% to sub-10% per annum effective 1 July 2026, and releasing promoter share pledge on 40.65% of equity, which should reduce finance costs and support margin recovery from Q2FY27 onwards.
Regulatory and commercial momentum: Wanbury cleared high‑profile inspections—Tanuku inspected by Australia’s TGA (enabling three additional API shipments once GMP certified) and Patalganga cleared Korea MFDS with zero observations—while expanding DMF filings into multiple geographies and receiving a No DME deficiency letter from the USFDA for Metformin API references.
Pharmaceuticals & Biotechnology
Pharmaceuticals
624 Cr
High Risk
14.5
34.8
-0.6
8.1
358.85
161.50
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
202.24 | 711 Cr | 24.36 | 2.54 | 0.00 | 10.79 | 12.00 | 6.38 | ||
129.25 | 702 Cr | 43.87 | 2.26 | 0.00 | -1.05 | 0.74 | 3.45 | ||
126.60 | 679 Cr | 183.60 | 2.31 | 0.00 | 1.97 | 5.07 | 0.69 | ||
163.20 | 634 Cr | 43.17 | 2.88 | 0.00 | 7.46 | 9.58 | 2.63 | ||
178.47 | 624 Cr | 14.52 | 8.06 | 0.00 | 51.51 | 27.98 | 10.39 | ||
257.00 | 595 Cr | 31.11 | 5.90 | 0.00 | 20.38 | 27.21 | 0.00 | ||
418.75 | 513 Cr | 76.27 | 6.13 | 0.00 | 5.14 | 6.71 | 7.66 | ||
| Median: 7 Co. | — | 178.47 | 634 Cr | 43.17 | 2.88 | 0.00 | 7.46 | 9.58 | 3.45 |
